Junshi Biosciences
[1877.HK]
Has a diversified R&D pipeline comprising over 21 drug candidates with therapeutic areas covering cancer, metabolic, autoimmune, neurological, and infectious diseases. Lead candidate, Toripalimab (JS001), reached over 1B RMB in sales, and expanded indications into nasopharyngeal carcinoma/urothelial carcinoma. Other product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai [more information]